Stablix
Latest round
- Series A
Last raised
- Jun 2021
Total raised
- $63M
Investors
- 5
About Stablix
Based in New York, US, and established in 2021, Stablix, Inc. is a biotechnology research company working on targeted protein stabilization (TPS) to provide transformative medications for patients with unmet medical needs. The company’s platform RESTORED™, which originated in a Columbia University laboratory, can remove the ubiquitin tags from specific proteins, and stabilize or drive an increase in target protein levels and activity. This is done by generating heterobifunctional small molecules that recruit deubiquitinase enzymes, or DUBs. The company’s medicines can be used for the treatment of oncology, immune-oncology, immunology, and rare diseases.
Who invested in Stablix
5 investors across 1 round
See all investors in Stablix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 3, 2021
Amount
$63M
Investors
Questions about Stablix
Who invested in Stablix?
Stablix has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Stablix raised?
Stablix has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Stablix last raise money?
Stablix's most recent round on record is a Series A, in Jun 2021.
What does Stablix do?
Based in New York, US, and established in 2021, Stablix, Inc.
Where is Stablix headquartered?
Stablix is headquartered in New York, US.
Which VCs invest in companies like Stablix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Stablix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Stablix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.